Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02868541
Other study ID # 2013-29
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 25, 2017
Est. completion date September 6, 2019

Study information

Verified date October 2022
Source Assistance Publique Hopitaux De Marseille
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective of this project is to study the prevalence of viruses and bacteria responsible for transmissible acute respiratory infections in the respiratory tract of pilgrims returning from the trip. The patients included, will be the consultant pilgrims to the traveler health center, and before leaving for Hajj. Based on the results obtained in previous studies, it is estimated that 200 pilgrims will be included each year, 600 in total (inclusion period of 3 years). Respiratory secretions are then collected by nasal swab and throat (swab) prior to departure for the hajj. In return, patients will be reconvened systematic consultation to record medical events potentially encountered during the trip, and it will again be performed the same nasal swabs and throat. It will then be performed on these samples' return from hajj "molecular detection (PCR and RT-PCR) of 35 viruses and bacteria respiratory tropism: influenza (3), RSV (2), metapneumovirus (1), Coronavirus (4), Parainfluenzavirus (4), enteroviruses (4), rhinovirus (1), adenovirus (6) bocavirus, polyomavirus (2), pneumococcus, Bordetella pertussis, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Haemophilus influenzae, Neisseria meningitidis and Coxiella burnetii. Samples "return of hajj" positive should be cultured for the isolation of the strain. For patients positive return, it will be done further research of these 35 viruses and bacteria on samples "start of hajj," the same method described above. In addition to this systematic consultation, and if symptoms return, the pilgrims will be seen in consultation for a diagnosis evaluation and therapeutic management. This study will shed light on the acquisition of microorganisms respiratory tropism during the stay and on the potential risks associated with the circulation of these pathogens after the trip.


Recruitment information / eligibility

Status Completed
Enrollment 905
Est. completion date September 6, 2019
Est. primary completion date September 6, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All travelers presenting during the study period in the service of international vaccination for mandatory meningococcal ACYW135 vaccination , - Affiliated to a social security insurance regime - Male or Female - Aged over 18 years - Having signed informed consent form - able to understand and answer the study questions Exclusion Criteria - Patients aged under 18 - Patient whose protocol compliance seems unlikely to investigator - Participant in another clinical trial or in exclusion period of a previous clinical trial, - Unable to understand the nature and objectives of the study, - Refusing to sign the informed consent form.

Study Design


Intervention

Other:
Naso pharyngeal swab
Naso pharyngeal swab

Locations

Country Name City State
France Assistance Publique Hopitaux de Marseille Marseille

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique Hopitaux De Marseille

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The number of new viruses and/or bacteria identified and characterized by respiratory and pharyngeal carriage among pilgrims between the departure and the return of Hajj up to 3 years
See also
  Status Clinical Trial Phase
Completed NCT03943654 - Improving Nighttime Access to Care and Treatment (Part 2)
Completed NCT05269290 - Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections Phase 3
Completed NCT06385821 - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus Phase 3
Not yet recruiting NCT05902702 - Isotonic Saline for Children With Bronchiolitis N/A
Not yet recruiting NCT04525118 - Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-based Study Platform
Completed NCT01431469 - Efficacy and Tolerance of a Follow-On Formula Fed to Children From 12-48 Months of Age in Salvador, Bahia, Brazil N/A
Completed NCT00981513 - Direct and Indirect Benefits of Influenza Vaccination in Schools and Households Phase 4
Recruiting NCT06183229 - Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza Phase 3
Completed NCT03274310 - FluSAFE: Flu SMS Alerts to Freeze Exposure N/A
Completed NCT03736096 - Molecular Diagnosis of Respiratory Viral Infections on Sputum From Cystic Fibrosis Patients
Completed NCT03189537 - Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections Phase 3
Completed NCT03028077 - Effects of GS-3K8 and GINst15 on Acute Respiratory Illness N/A
Enrolling by invitation NCT01286285 - Surveillance of Influenza in Paediatric Intensive Care Units in Bavaria N/A
Completed NCT03840135 - Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI Phase 3
Completed NCT01488435 - Efficacy and Tolerance of a Follow-On Formula Fed to Children From 36-48 Months of Age N/A
Not yet recruiting NCT00545961 - Middle Meatal Bacteriology During Acute Respiratory Infection in Children Phase 4
Completed NCT05273619 - Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection Phase 3
Recruiting NCT04415827 - Energy Supply in Athletes and Untrained Persons With Bronchopulmonary Diseases N/A
Completed NCT03459391 - Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers Phase 1
Withdrawn NCT04938323 - Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly Phase 2/Phase 3